These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

52 related items for PubMed ID: 2641039

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Morphine antagonists (pentazocine, nalorphine, naloxone and buprenophine)].
    Fournier T, Besserve P, Lefèvre P, Lephay A, Ossart M.
    Cah Anesthesiol; 1988 May; 36(3):223-34. PubMed ID: 2840178
    [No Abstract] [Full Text] [Related]

  • 27. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.
    Teoh SK, Mendelson JH, Mello NK, Kuehnle J, Sintavanarong P, Rhoades EM.
    J Clin Psychopharmacol; 1993 Apr; 13(2):87-99. PubMed ID: 8463453
    [Abstract] [Full Text] [Related]

  • 28. Blocking of enhanced sensitivity to behavioral effects of naloxone induced by narcotic agonists in rats.
    Jain R, Ray R.
    Indian J Physiol Pharmacol; 2003 Oct; 47(4):407-14. PubMed ID: 15266952
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Characterization of the discriminative stimulus effects of buprenorphine in pigeons.
    Galici R, Brandt MR, France CP.
    Psychopharmacology (Berl); 2002 Mar; 160(2):132-9. PubMed ID: 11875630
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
    Bozinoff N, Tardelli VS, Rubin-Kahana DS, Le Foll B.
    Harm Reduct J; 2022 Oct 13; 19(1):113. PubMed ID: 36229831
    [Abstract] [Full Text] [Related]

  • 36. In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.
    Bossert JM, Kiyatkin EA, Korah H, Hoots JK, Afzal A, Perekopskiy D, Thomas S, Fredriksson I, Blough BE, Negus SS, Epstein DH, Shaham Y.
    Biol Psychiatry; 2020 Dec 15; 88(12):935-944. PubMed ID: 32305216
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Combination of naloxone with buprenorphine in humans.
    Weinhold LL, Bigelow GE, Preston KL.
    NIDA Res Monogr; 1989 Dec 15; 95():485. PubMed ID: 2641039
    [No Abstract] [Full Text] [Related]

  • 40. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
    La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB.
    Clin Pharmacol Ther; 2008 Jan 15; 83(1):144-52. PubMed ID: 17568402
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.